Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Current research on pharmacologic and regenerative therapies for osteoarthritis

    Access Status
    Open access via publisher
    Authors
    Zhang, W.
    Ouyang, H.
    Dass, Crispin
    Xu, J.
    Date
    2016
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Zhang, W. and Ouyang, H. and Dass, C. and Xu, J. 2016. Current research on pharmacologic and regenerative therapies for osteoarthritis. Bone Research. 4.
    Source Title
    Bone Research
    DOI
    10.1038/boneres.2015.40
    ISSN
    2095-4700
    School
    School of Pharmacy
    URI
    http://hdl.handle.net/20.500.11937/32005
    Collection
    • Curtin Research Publications
    Abstract

    Osteoarthritis (OA) is a degenerative joint disorder commonly encountered in clinical practice, and is the leading cause of disability in elderly people. Due to the poor self-healing capacity of articular cartilage and lack of specific diagnostic biomarkers, OA is a challenging disease with limited treatment options. Traditional pharmacologic therapies such as acetaminophen, non-steroidal anti-inflammatory drugs, and opioids are effective in relieving pain but are incapable of reversing cartilage damage and are frequently associated with adverse events. Current research focuses on the development of new OA drugs (such as sprifermin/recombinant human fibroblast growth factor-18, tanezumab/monoclonal antibody against ß-nerve growth factor), which aims for more effectiveness and less incidence of adverse effects than the traditional ones. Furthermore, regenerative therapies (such as autologous chondrocyte implantation (ACI), new generation of matrix-induced ACI, cell-free scaffolds, induced pluripotent stem cells (iPS cells or iPSCs), and endogenous cell homing) are also emerging as promising alternatives as they have potential to enhance cartilage repair, and ultimately restore healthy tissue. However, despite currently available therapies and research advances, there remain unmet medical needs in the treatment of OA. This review highlights current research progress on pharmacologic and regenerative therapies for OA including key advances and potential limitations.

    Related items

    Showing items related by title, author, creator and subject.

    • Ovarian cancer stem cells and their role in drug resistance
      Pieterse, Z.; Amaya-Padilla, M.; Singomat, T.; Binju, M.; Madjid, B.; Yu, Y.; Kaur, Pritinder (2019)
      Ovarian cancer is typically diagnosed at advanced stages (III or IV), with metastasis ensuing at stage III. Complete remission is infrequent and is not achieved in almost half of the women diagnosed with ovarian cancer. ...
    • A Narrative Review of Dignity Therapy Research
      Bentley, B.; O'Connor, Moira; Shaw, J.; Breen, Lauren (2017)
      Introduction: Dignity therapy is an end-of-life psychological intervention that focuses on the creation of a legacy document to alleviate end-of-life distress. Dignity therapy is based on an empirical model of dignity at ...
    • Biophysical characterization of layer-by-layer synthesis of aptamer-drug microparticles for enhanced cell targeting
      Tan, K.; Danquah, M.; Sidhu, Amandeep; Lau, Shiew Wei; Ongkudon, C. (2017)
      © 2017 American Institute of Chemical Engineers. Targeted delivery of drug molecules to specific cells in mammalian systems demonstrates a great potential to enhance the efficacy of current pharmaceutical therapies. ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.